Gene targeting in ischemic heart disease and failure: Translational and clinical studies

Shaina R. Eckhouse, Jeffrey A. Jones, Francis G. Spinale

Research output: Contribution to journalComment/debate

10 Scopus citations


Alternative and innovative targeted strategies hold relevance in improving the current treatments for ischemic heart disease (IHD). One potential treatment modality, gene targeting, may provide a unique alternative to current IHD therapies. The principal function of gene targeting in IHD is to augment the expression of an endogenous gene through amplification of an exogenous gene, delivered by a plasmid or a viral vector to enhance myocardial perfusion, and limit the long-term sequelae. The initial clinical studies of gene targeting in IHD were focused upon induction of angiogenic factors and the outcomes were equivocal. Nevertheless, significant advancements have been made in viral vectors, mode of delivery, and potentially relevant targets for IHD. Several of these advancements, particularly with a focus on translational large animal studies, are the focus of this review. The development of novel vectors with prolonged transduction efficiency and minimal inflammation, coupled with hybrid perfusion-mapping delivery devices, and improving the safety of vector use and efficacy of gene systems are but a few of the exciting progresses that are likely to proceed to clinical studies in the near future.

Original languageEnglish
Pages (from-to)1-11
Number of pages11
JournalBiochemical Pharmacology
Issue number1
StatePublished - Jan 1 2013


  • Adeno-associated virus
  • Adenovirus
  • Gene therapy
  • Ischemia
  • Myocardial infarction
  • Plasmid


Dive into the research topics of 'Gene targeting in ischemic heart disease and failure: Translational and clinical studies'. Together they form a unique fingerprint.

Cite this